mlgreen8753
With a 20% interest acquired in a recent merger in a biotech company, Mentor Capital has increased it's assets by $3.74 per share. What's more exciting is the company they have merged with, Quantum Immunologics (QI). QI has initiated FDA authorized clinical trials for a new breast cancer treatment that exposes cancer cells so the immune can fight them directly. The treatment is safer and has much milder side effects than other treatments. The marketing of this treatment can have a dramatic effect on the stock price of Mentor Capital making this a ground level opportunity for those who get in now.
